-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024
Empower your strategies with our Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease, an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision; dark, empty spots in the center of vision; and difficulty reading or performing detail work. Risk factors include arteriosclerosis,...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewEpidermolysis Bullosa – Drugs In Development, 2024
Empower your strategies with our Epidermolysis Bullosa – Drugs In Development, 2024 report and make more profitable business decisions. Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin; deformity or loss of fingernails and toenails; internal blistering including on the throat, esophagus, upper airway, stomach, intestines, and urinary tract; skin thickening on palms and soles of the feet (hyperkeratosis); and scalp blistering, scarring, and hair loss...
-
Product Insights
NewOptic Neuropathy – Drugs In Development, 2024
Empower your strategies with our Optic Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, smoking, alcohol, cancer treating drugs, stress related chemicals, some antibiotics, and cyanogens. The Optic Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage...
-
Product Insights
Hydrogels Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hydrogels Pipeline Market Report Overview Hydrogels include dressings that consist of 96% water with a matrix of insoluble polymers embedded in it. The former helps to maintain a moist wound environment while the latter facilitates absorption of wound exudates. These dressings are available in the form of tubes and sheets and both of them are tracked under this segment. Hydrogels are segmented into antimicrobial and non-antimicrobial hydrogel dressings. The Hydrogels pipeline market research report provides comprehensive information about the Hydrogels...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ART-0380 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-0380 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-0380 in Solid Tumor Drug Details: ART-0380 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prademagene Zamikeracel in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prademagene Zamikeracel in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prademagene Zamikeracel in Epidermolysis Bullosa Drug Details: Prademagene zamikeracel (EB-101) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-2 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-2 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RP-2 in Metastatic Colorectal Cancer Drug Details:RP-2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PanBlok in Pandemic Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PanBlok in Pandemic Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PanBlok in Pandemic InfluenzaDrug Details:PanBlok (UMN-0501) is under development for the treatment of pandemic...
-
Company Profile
Abeona Therapeutics Inc – Company Profile
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals Inc, is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe life-threatening rare diseases. The company’s lead programs include EB-101, ABO-101 and ABO-102 adeno-associated virus. Abeona develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-202 (AAV-CLN1) gene therapy for the treatment of infantile Batten disease (INCL), ABO-201 (AAV-CLN3) gene therapy for Juvenile Batten disease (JNCL) and more. The company has partnerships for the...
Add to Basket